Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Decitabine + Enzalutamide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Decitabine||Dacogen||5-aza-2-deoxycytidine||DNMT inhibitor (Pan) 5||Dacogen (decitabine) is cytidine analog that incorporates into DNA and forms covalent bonds with DNA methyltransferases (DNMTs), resulting in decreased DNMT activity and hypomethylation, and potentially leading to reduced tumor growth (PMID: 28159832, PMID: 25130173). Dacogen (decitabine) is FDA approved for use in patients with myelodysplastic syndromes (FDA.gov).|
|Enzalutamide||Xtandi||MDV3100|ASP9785||Hormone - Anti-androgens 38||Xtandi (enzalutamide) is a second-generation small molecule androgen receptor (AR) inhibitor that inhibits AR signaling, thereby resulting in decreased tumor growth (PMID: 24009414, PMID: 25945058). Xtandi (enzalutamide) is FDA approved for use in patients with castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03709550||Phase Ib/II||Decitabine + Enzalutamide||Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer||Withdrawn||USA||0|